Identification of Anziaic Acid, a Lichen Depside from Hypotrachyna sp., as a New Topoisomerase Poison Inhibitor by Cheng, Bokun et al.
 
Identification of Anziaic Acid, a Lichen Depside from Hypotrachyna
sp., as a New Topoisomerase Poison Inhibitor
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Cheng, Bokun, Shugeng Cao, Victor Vasquez, Thirunavukkarasu
Annamalai, Giselle Tamayo-Castillo, Jon Clardy, and Yuk-Ching
Tse-Dinh. 2013. Identification of anziaic acid, a lichen depside
from hypotrachyna sp., as a new topoisomerase poison inhibitor.
PLoS ONE 8(4): e60770.
Published Version doi:10.1371/journal.pone.0060770
Accessed February 19, 2015 12:06:48 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11361904
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAIdentification of Anziaic Acid, a Lichen Depside from
Hypotrachyna sp., as a New Topoisomerase Poison
Inhibitor
Bokun Cheng
1, Shugeng Cao
2, Victor Vasquez
3, Thirunavukkarasu Annamalai
1,4,
Giselle Tamayo-Castillo
3, Jon Clardy
2, Yuk-Ching Tse-Dinh
1,4*
1Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York, United States of America, 2Department of Biological Chemistry and
Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America, 3Unidad Estrategica de Bioprospeccion, Instituto Nacional de
Biodiversidad (INBio) and Escuela de Quı ´mica, Universidad de Costa Rica, San Jose ´, Costa Rica, 4Department of Chemistry and Biochemistry, Florida International
University, Miami, Florida, United States of America
Abstract
Topoisomerase inhibitors are effective for antibacterial and anticancer therapy because they can lead to the accumulation
of the intermediate DNA cleavage complex formed by the topoisomerase enzymes, which trigger cell death. Here we report
the application of a novel enzyme-based high-throughput screening assay to identify natural product extracts that can lead
to increased accumulation of the DNA cleavage complex formed by recombinant Yersinia pestis topoisomerase I as part of a
larger effort to identify new antibacterial compounds. Further characterization and fractionation of the screening positives
from the primary assay led to the discovery of a depside, anziaic acid, from the lichen Hypotrachyna sp. as an inhibitor for
both Y. pestis and Escherichia coli topoisomerase I. In in vitro assays, anziaic acid exhibits antibacterial activity against Bacillus
subtilis and a membrane permeable strain of E. coli. Anziaic acid was also found to act as an inhibitor of human
topoisomerase II but had little effect on human topoisomerase I. This is the first report of a depside with activity as a
topoisomerase poison inhibitor and demonstrates the potential of this class of natural products as a source for new
antibacterial and anticancer compounds.
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Introduction
DNA topoisomerases are ubiquitous enzymes that play essential
roles in controlling the topological state of DNA to facilitate and
remove barriers for vital cellular functions including DNA
replication, transcription, recombination and repair [1,2]. Topo-
isomerase enzymes utilize an active site tyrosine side chain for
nucleophilic attack of the DNA phosphodiester linkage, resulting
in the formation of a covalent reaction intermediate with the
tyrosine covalently linked to the phosphoryl end of the cleaved
DNA. Topoisomerase poison inhibitors can promote cell death by
increasing the accumulation of this covalent protein-DNA
intermediate [3]. These inhibitors can therefore be highly effective
antibacterial and anticancer agents. A number of topoisomerase
poison inhibitors have been isolated as natural products. These
include camptothecin which targets type IB human topoisomerase,
and has been followed by the development of more soluble analogs
that are useful in clinical treatment of different types of cancers [4].
Quinolones are highly effective synthetic molecules that act as
poison inhibitors targeting type IIA bacterial topoisomerases [5].
New antibacterial agents acting on a novel target are very much
needed to combat the serious global health problem of bacterial
pathogens resistant to quinolones and other existing antibacterial
therapeutics [6,7]. Every bacterium has at least one type IA DNA
topoisomerase that could potentially be targeted by a new class of
topoisomerase poison [8]. Recombinant bacterial topoisomerase I
with a mutation mimicking the effect of topoisomerase poison has
been used to demonstrate that the accumulation of topoisomerase
I covalent cleavage intermediate indeed leads to bacterial cell
death [9–11]. The cell death mechanism involves reactive oxygen
species [12], as demonstrated for quinolones and other bactericidal
antibiotics [13,14]. A target based high throughput screening
(HTS) assay was developed for bacterial topoisomerase I to
identify agents that can lead to higher levels of DNA cleavage
product. Yersinia pestis can potentially be used as a bioweapon so
the HTS assay was optimized for Y. pestis topoisomerase I. Pilot
screening was carried out against collections of small molecules
and natural product extracts. Great diversity of molecular
structures can be found among natural products and antibacterial
activities can often be discovered in natural products from various
sources [15]. Follow up experiments for one of the natural product
screening hits led to the identification of the depside anziaic acid as
the active compound. Our results show that a depside can act as a
topoisomerase poison, suggesting that this class of natural product
could be exploited to provide novel leads for antimicrobial and
anticancer agents.
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Topoisomerase Enzymes
Recombinant Y. pestis and E. coli DNA topoisomerase I were
purified as previously described [9,16]. Human topoisomerase I
and II were purchased from TopoGen. E. coli DNA gyrase was
purchased from New England BioLabs.
HTS Assays
Oligonucleotide substrate (59-CTTATGCAATGCGCTQTT-
GGGCAAACCAAGAGAGCATAAG-39) with CAL Fluor Red
610 fluorophore at the 59-end and BHQ-2 quencher at the 39-end
was custom synthesized by Biosearch Technologies. This oligo-
nucleotide forms a stem-loop structure with a single cleavage site
for Y. pestis and E. coli topoisomerase I in the single-stranded loop
region indicated by the arrow. Ten microliter aliquots of a premix
of 100 nM oligo substrate, 100 nM Y. pestis topoisomerase I in
10 mM Tris-HCl, pH 8, 0.5 mM MgCl2 were dispensed into 384-
well Corning 3821 low volume plates followed by pin transfers of
33 nL of library compounds at the NERCE/NSRB HTS facility.
DMSO was used as negative control at 0.33% while compound
NSC28086 was used as a positive control at 0.25 mM concentra-
tion. After 60 min at room temperature, fluorescence (Ex/Em
wavelengths of 590/610 nm) was recorded with the Envision3
plate reader. The assay was carried out in duplicates for 7,105
small molecules and 2,816 natural product extracts at NERCE/
NSRB.
Natural Product Library
The natural product libraries, which were prepared in Costa
Rica (collection permits 307-2003-OFAU, R-CM-03-2006, R-
CMINBio-06-2006, R-CM-INBio-082-2009, R-CM-INBio-04-
2009, R-CM-INBio-088-2009 and R-CM-INBio-094-2010), con-
sisted mainly of pre-fractionated extracts from microbial sources,
such as fungal endophytes and marine bacteria, although extracts
from other sources such as marine invertebrates, cyanobacteria
and lichens were also included [17]. Extracts were suspended in
dimethyl sulfoxide (DMSO) at a concentration of ,15 mg/mL.
The compound libraries were stored at 220uC in desiccated
storage containers. Screening of the libraries ICBG16 (1408),
NCDDG7 (1056) and NCDDG8 (352) yielded two confirmed hits,
PL2050/C13 and PL2050/D12. Both hits were originated from
the same lichen sample, Hypotrachyna sp.
Compound Isolation and Identification
Lichen sample collection and extraction. Approximately
5.25 g of the lichen Hypotrachyna sp. (Lecanorales, Parmeliaceae)
collected at Quetzales National Park, Central Pacific, Costa Rica
(Permit R-CM-INBio-30-2007-OT) on February 2009, afforded
4.53 g of dry material upon drying. The dry powder was extracted
with 100 mL 95% ethanol in an ultrasonic bath for 20 minutes
and repeated 3 times, to yield 807.4 mg of crude extract.
Isolation and identification. A solid phase extraction
method was employed (Figure 1). Approximately 356.1 mg of
crude extract of Hypotrachyna adsorbed in Diaion HP-20ss (3:1)
were loaded on a column containing 4 g of Diaion HP-20ss and
eluted with 15 mL each of water:ethanol 8:2, 1:1, 2:8, ethanol and
isopropanol:dichloromethane 8:2 to afford five fractions. Fraction
4 afforded 188.5 mg of SScode 86608. A HPLC separation
(HPLC Waters 600 with a Waters detector PDA 996) was
conducted on fraction 4 (44.1 mg) using isocratic conditions (70%
acetonitrile:water for 30 min; Phenomenex Luna, C18, 250 X
10 mm, 10 micron) to obtain subfraction 5, SScode 86610,
(24.7 mg, TR 18 min). SScode 86610 was identified as anziaic acid
by comparison of NMR (Figure S1, S2, Table S1) and mass
spectroscopy (Figure S3) data with literature values [18].
Topoisomerase Activity Assays
Inhibition of relaxation activity of 10 ng of Y. pestis and E. coli
topoisomerase I were assayed with 250 ng of supercoiled pBAD/
Thio plasmid DNA substrate purified by CsCl gradient. The
relaxation reaction was carried out in 20 mL of 10 mM Tris-HCl,
pH 8.0, 50 mM NaCl, 0.1 mg/mL gelatin with 0.5 mM MgCl2. A
higher concentration of 6 mM MgCl2 was used in some
experiments. Tween 20, when present was at 0.0025%. After
30 min at 37uC, the reactions were terminated and analyzed by
agarose gel electrophoresis as previously described [16,19].
The effect of inhibitors on the accumulation of DNA cleavage
product for E. coli topoisomerase I was assayed with 59-
32P-labeled
216 base long single-stranded DNA generated by denaturation of
a PCR product [20]. The labeled DNA (50 ng) was incubated with
100 ng of E. coli topoisomerase I in 5 mL of 10 mM Tris-HCl,
pH 8.0, 2 mM MgCl2 at 37uC for 30 min to allow the
Figure 1. Isolation tree of anziaic acid.
doi:10.1371/journal.pone.0060770.g001
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reaction was terminated by the addition of an equal volume of
sequencing gel loading buffer. The level of DNA cleavage products
was analyzed by electrophoresis in a 7% sequencing gel followed
by Phosphor-Imager analysis of the dried gel.
Human topoisomerase I and IIa (from TopoGen) relaxation
assays and E. coli DNA gyrase (from New England BioLab)
supercoiling assay were carried out as recommended by the
suppliers. Relaxed plasmid DNA substrate for DNA gyrase was
purchased from New England BioLabs. Human topoisomerase I
and II DNA cleavage assays were carried out as described
previously [19]. For gyrase DNA cleavage assay, enzyme-DNA
reactions were treated with 1% SDS for 5 min followed by
proteinase K (0.5 mg/mL) digestion for 30 min before analysis in
agarose gel in the presence of ethidium bromide.
Antibacterial Assay
Inhibition of bacterial growth by natural product extracts was
measured initially in 96 well plates with lid in a Perkin Elmer
HTS7000 Plus plate reader with brief shaking at 20 min intervals
at 37uC. IC50s were defined as concentrations that inhibited
growth by 50% after 24 h as determined by absorption readings at
600 nm.
MICs of isolated inhibitor against different bacterial strains
grown in cation-adjusted Mueller- Hinton Broth were measured
with standard microdilution procedures. Complete growth inhibi-
tion was recorded after 24 h in a 37uC incubator.
Mammalian Cell Cytotoxicity Assay
Human pulmonary artery endothelial cells (HPAEC) were
obtained from Cell Applications, Inc. (San Diego, CA, USA) and
cultured in endothelial cell media supplemented with subculture
Reagent kit. Approximately 5000 cells in 100 mL were placed in
each well of a 96-well plate. After the addition of an inhibitor or
DMSO, cells were incubated overnight before assay for viability
with the Promega CellTiter-Glo Luminescent Cell Viability Assay
according to the manufacturer’s protocol.
Results
Validation of HTS Assay
The fluorescence emission of the fluorophore at the 59-end the
oligonucleotide substrate is quenched by the quencher at the 39-
end. Shifting of the topoisomerase I cleavage-religation equilibri-
um towards DNA cleavage is expected to lead to an increase in
fluorescence emission. This was validated using the G116S mutant
form of E. coli topoisomerase I previously shown to be defective in
DNA religation [9]. Addition of this mutant enzyme resulted in
.5 fold increase in fluorescence signal over the wild-type enzyme
when fluorescence was measured with a BioTek Synergy HT plate
reader. A small molecule that can be used as positive control
compound NSC28086, was identified from a separate set of
analysis carried out on the NCI Diversity Set of compounds to
inhibit relaxation activity of E. coli and Y. pestis topoisomerase I,
and increase level of the cleavage product (results to be published).
This compound can also result in .5 fold increase in fluorescence
signal over DMSO control when present at 0.25 mM concentra-
Figure 2. Inhibition of E. coli topoisomerase I relaxation activity by lichen extracts and fractions. (a) Secondary assay of natural product
hits from HTS using negatively supercoiled DNA plasmid substrate. Lane 1: no enzyme. Relaxation activity of 10 ng of E. coli topoisomerase I was
assayed in the presence of DMSO (lane 2) or 80 mg/mL of natural product extracts hits (lane 3–12). Extracts PL2050/C13 and PL2050/D12 prepared
from lichen Hypotrachyna sp. samples were present in lanes 7 and 8 respectively. (b) Assay of HP20ss fractionated extracts of lichen Hypotrachynasp.
samples. Lane 1: no enzyme control. Lane 2: Enzyme with DMSO control. Lanes 3–20: serial 4-fold dilutions (12, 3, 0.75 mg/mL) of unfractionated total
extract (lanes 3–5), Fraction 1 (lanes 6–8), Fraction 2 (lanes 9–11), Fraction 3 (lanes 12–14), Fraction 4 (lanes 15–17), Fraction 5 (lanes 18–20). S:
supercoiled plasmid DNA substrate. N: nicked plasmid DNA. Ro: Relaxed closed plasmid DNA. PR: partially relaxed plasmid DNA.
doi:10.1371/journal.pone.0060770.g002
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screening center to achieve a Z’ factor of 0.7–0.8 on different days.
Pilot Screening of Small Molecule and Natural Product
Library
Pilot screening was carried out in duplicate for 7,105 small
molecules and 2,816 natural product extracts at NERCE/NSRB.
A column of negative control (DMSO) was included in each plate.
The signal from each compound well was divided by the average
of the negative control signal from the same plate. Compounds
that resulted in ratio of .1.6 in both duplicated assays were
selected as hits corresponding to a hit rate of 0.3% after
elimination of compounds with high intrinsic fluorescence in
counter assay. The thirty selected hits included ten natural product
extracts.
Secondary Assay
One microliter of 15 mg/mL selected natural product extract
hits was available for confirmation of the primary assay result
using the BioTek HT plate reader at New York Medical College.
From the 10 natural product extracts among the primary assay
hits, extracts PL2050/C13 and PL2050/D12 were found to result
in a fluorescence signal ratio of 3.6 and 1.5 respectively at 50 mg/
mL concentration when compared to DMSO control. In the
secondary assay, these extracts were tested for inhibition of the
relaxation activity of E. coli topoisomerase I at 80 mg/mL.
Complete inhibition of relaxation activity was observed for
PL2050/C13 and partial inhibition was seen for PL2050/D12
(Figure 2a). Both of these confirmed hits were prepared from
lichen Hypotrachyna sp. samples. Extract of this lichen was
prioritized for further studies over the other extracts that also
showed topoisomerase inhibition.
Figure 3. Effect of lichen Hypotrachyna sp. HP20ss fractions and
anziaic acid on cleavage product accumulation by E. coli
topoisomerase I. Single-stranded DNA substrate labeled at the 59-
end with
32P (S) was incubated with enzyme in the presence of 2 mM
MgCl2. No enzyme (lane 1), enzyme with DMSO (lane 2). a.
Unfractionated total extract (lanes 3, 4), fraction 3 (lanes 5, 6), fraction
4 (lanes 7, 8), fraction 5 (lanes 9, 10) with the extract or fraction
compounds present at 3.1 mg/mL (lanes 3, 5, 7, 9) or 12.5 mg/mL (lanes
4, 6, 8, 10). b. Anziaic acid was present at 0.9 mM (lanes 3), 1.8 mM (lanes
4), 3.7 mM (lanes 5) and 7.2 mM (lanes 6).
doi:10.1371/journal.pone.0060770.g003
Table 1. Growth inhibition of E. coli strain BAS3023 by lichen
Hypotrachyna sp. HP20ss fractions.
Fraction IC50 Growth inhibition (mg/mL)
Total extract 12.5
Fraction 1 negative
Fraction 2 negative
Fraction 3 25
Fraction 4 5
Fraction 5 5
doi:10.1371/journal.pone.0060770.t001
Figure 4. Inhibition of Relaxation activity of E. coli topoisom-
erase I by anziaic acid. Assay was carried out in the presence of
DMSO or the indicated concentration of anziaic acid with (a) 0.5 mM
MgCl2, (b) 0.5 mM MgCl2+0.0025% Tween 20, (c) 6 mM MgCl2, (d) 6 mM
MgCl2+0.0025% Tween 20. -: no enzyme control.
doi:10.1371/journal.pone.0060770.g004
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Inhibitor with Antibacterial Activity
Lichen Hypotrachyna sp. extract was subject to chromatogra-
phy fractionation. After HP20ss fractionation, fractions 3–5 were
found to inhibit the relaxation activity of E. coli topoisomerase I,
with fraction 4 being the most potent (Figure 2b). Antibacterial
activity was also monitored with permeable E. coli strain BAS3023
with the imp4213 mutation conferring permeability to small
molecules [21,22] and was found in fractions 3–5 (Table 1).
Inhibitors acting with a topoisomerase poison inhibitor mechanism
are of greater interest. These can be identified from the effect of
the inhibitors on the level of DNA cleavage products formed by
bacterial topoisomerase I enzyme from 59-
32P labeled single-
stranded DNA. The results in Figure 3a showed that only fraction
4 resulted in increased accumulation of DNA cleavage product
formed by E. coli topoisomerase I as expected from a topoisom-
erase poison inhibitor. Decrease in cleavage product was seen in
the presence of materials from fraction 3 and 5 (Figure 3a).
Compounds present in fractions 3 and 5 likely inhibit the
relaxation activity by inhibition of the DNA binding or cleavage
steps. Further separation of material in Fraction 4 led to the
identification of anziaic acid as the active compound (Figure 3b).
Anziaic acid exhibited antibacterial activity against Bacillus subtilis
(ATCC 6633) with an MIC of 6 mg/mL (14 mM), and E. coli strain
BAS3023 (MIC=12 mg/mL or 28 mM), but not for E. coli strain
BW27784 without permeability mutation.
Effect of Detergent and Mg
2+ Concentration on
Inhibitory Activity
The presence of 0.0025% Tween 20 had only a minor effect
on the inhibition of the E. coli topoisomerase I relaxation
activity, indicating that anziaic acid is not acting as a
promiscuous inhibitor (Figure 4). The structure of anziaic acid
suggests that it may act as a chelator of Mg
2+. Divalent ions are
required for the religation step and the relaxation activity of
bacterial topoisomerase I [23,24]. However, there is no increase
in IC50 for relaxation inhibition when Mg
2+ concentration was
shifted from 0.5 to 6 mM (Figure 4). The inhibition by anziaic
acid was more effective at the higher Mg
2+ concentration
(IC50=19mM in the presence of Tween 20). These mechanistic
characteristics are also true for the inhibition of relaxation
activity of Y. pestis topoisomerase I by anziaic acid with
IC50=14mM in the presence of Tween 20 and 6 mM Mg
2+
(Figure 5). The increase in intermediate cleavage product
Figure 5. Inhibition of Relaxation activity of Y. pestis topoisomerase I by anziaic acid in the presence of different concentrations of
Mg
2+. Assays were carried out in the presence of 0.0025% Tween 20 and MgCl2 concentration of 0.5 mM (a) or 6 mM (b). -: no enzyme control.
Anziaic acid is present at the concentration indicated.
doi:10.1371/journal.pone.0060770.g005
Figure 6. Effect of anziaic acid on type IB human topoisomer-
ase I activity. (a) Assay of relaxation activity –1 U of enzyme was used
in each relaxation reaction with 250 ng of supercoiled plasmid DNA. (b)
DNA cleavage assay with 5 U of enzyme. Gel electrophoresis was
carried out in the presence of 0.5 mg/mL ethidium bromide and
camptothecin was used as a positive control at 62.5 mM (C1) or 125 mM
(C2). -: no enzyme. S: supercoiled plasmid DN substrate. N: nicked
plasmid DNA. Ro: Relaxed closed plasmid DNA. PR: partially relaxed
plasmid DNA. CC: Covalently closed circular DNA.
doi:10.1371/journal.pone.0060770.g006
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Mg
2+ concentration that is far higher than the concentration of
anziaic acid (0.9–7.2 mM) present in the DNA cleavage assay
(Figure 3b). It can thus be concluded that inhibition did not
result from chelation of free Mg
2+ by anziaic acid. However,
the results did not rule out interference of divalent ions bound
at the active site of bacterial topoisomerase I by anziaic acid as
the mechanism of inhibition. The concentration of anziaic acid
Figure 7. Effect of anziaic acid on E. coli DNA gyrase activity. (a) Assay of supercoiling activity with 1 U of enzyme and 250 ng of relaxed
plasmid DNA substrate. (b) DNA cleavage assay with 5 U of enzyme. Gel electrophoresis was carried out in the presence of 0.5 mg/mL ethidium
bromide. Positive controls – F: 100 mM levofloxacin; N: 100 mM norfloxacin. S: supercoiled plasmid DNA substrate. N: nicked plasmid DNA. Ro: Relaxed
closed plasmid DNA. PR: partially relaxed plasmid DNA. L: linear DNA CC: covalently closed circular DNA.
doi:10.1371/journal.pone.0060770.g007
Figure 8. Effect of anziaic acid on human topoisomerase IIa activity. (a) Assay of relaxation activity –1 U of enzyme was used in each
relaxation reaction with 250 ng of supercoiled plasmid DNA in the presence of 0.0025% Tween 20. (b) DNA cleavage assay with 5 U of enzyme. Gel
electrophoresis was carried out in the presence of 0.5 mg/mL ethidium bromide and m-AMSA was used as a positive control at 25 mM (A1) or 8 mM
(A2). -: no enzyme. S: supercoiled plasmid DNA substrate. N: nicked plasmid DNA. Ro: Relaxed closed plasmid DNA. PR: partially relaxed plasmid DNA.
L: linear DNA. CC: covalently closed circular DNA.
doi:10.1371/journal.pone.0060770.g008
Depside Anziaic Acid: A New Topoisomerase Inhibitor
PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e60770sufficient for increase in DNA cleavage product accumulation
(Figure 3b) is .20 fold lower than the IC50 for relaxation of the
overall catalytic cycle (Figure 4). This is consistent with anziaic
acid acting as a poison inhibitor.
Assays for Inhibition of other DNA Topoisomerases
To further evaluate the specificity of topoisomerase inhibition
by anziaic acid, the effect on type IB human topoisomerase I was
evaluated. The IC50 for relaxation inhibition was found to be .10
fold higher than the IC50 for inhibition of bacterial type IA
topoisomerases (Figure 6a). Moreover, anziaic acid at up to
230 mM did not result in increase in cleavage product formed by
human topoisomerase I (Figure 6b).
The supercoiling activity of E. coli DNA gyrase was assayed
using relaxed plasmid DNA substrate along with assay of DNA
cleavage product accumulation to determine the effect of anziaic
acid on this type IIA DNA topoisomerase. The results showed that
while anziaic acid can inhibit the supercoiling activity of DNA
gyrase (IC50=19mM), it did not act as a poison inhibitor for DNA
gyrase over the range of concentrations tested, in contrast to the
quinolone antibiotics levofloxacin and norfloxacin (Figure 7).
Human topoisomerase IIa is also a type IIA topoisomerase.
Anziaic acid was found not only to be an inhibitor of human
topoisomerase IIa relaxation activity (IC50=35mM) when assayed
with supercoiled plasmid DNA (Figure 8a), but was also found to
act as a poison inhibitor for increase of the human topoisomerase
IIa linear DNA cleavage intermediate at concentration below this
IC50 (Figure 8b).
Cytotoxicity Evaluation
To determine potential cytotoxicity of anziaic acid, human
pulmonary artery endothelial cells were treated with different
concentrations of anziaic acid. Luciferase linked ATP assay was
used to measure viability. When compared to DMSO control,
concentration of 21 mM anziaic acid was found to result in fifty
percent loss of viability.
Discussion
Natural products are a valuable resource of diverse chemical
structures with potentially useful therapeutic activity. There is an
urgent need for novel antibacterial compound due to the increased
prevalence of drug resistant pathogens in both hospital and
community settings. Bacterial topoisomerase I is a promising new
target for antibacterial therapy, but inhibitor prototypes need to be
identified to initiate the drug discovery efforts. Topoisomerase
poison inhibitors are especially valuable as antibacterial or
anticancer drugs because of the active cell killing mechanism that
requires only a small percentage of the target topoisomerase
molecules be trapped on chromosomal DNA as a result of the
poison inhibitor action.
A HTS assay was used to explore a collection of natural product
extracts for poison inhibitors targeting Y. pestis topoisomerase I,
which shares 85% sequence identity with the more extensively
characterized E. coli topoisomerase I. The two enzymes have
shown identical properties in previous biochemical studies
[9,16,25]. Y. pestis topoisomerase I was used in the initial HTS
because the NERCE/NSRB resource can be readily available for
this biodenfense related target. Two of the primary assay hits
corresponded to lichen Hypotrachyna sp. extracts. While the extracts
likely contained multiple compounds capable of inhibition of the
relaxation activity of bacterial topoisomerase I, a unique fraction
from the HP-20ss fractionation showed properties expected from a
topoisomerase poison inhibitor. Further purification led to the
identification of the depside anziaic acid as a bacterial topoisom-
erase I poison inhibitor. While the ester linkage in anziaic acid
could potentially be hydrolyzed, mass spectrometry analysis
confirmed the continued presence of the intact compound
following incubation in the topoisomerase assay buffer (data not
shown). Preliminary SAR studies (results to be published) showed
that synthesized compounds with structures identical or similar to
the products expected from the ester hydrolysis of anziaic acid did
not inhibit bacterial growth or topoisomerase activity, providing
support that anziaic acid is the active inhibitor.
Bacterial topoisomerase I enzymes belong to the type IA
topoisomerase subfamily. This class of enzyme shares no similarity
in sequence or mechanism with the type IB topoisomerase
subfamily other than the use of an active site tyrosine nucleophile.
Anziaic acid had an extremely weak effect on the human
topoisomerase I, a type IB enzyme, indicating that it is not a
non-specific inhibitor for all DNA enzymes. It does not act as a
promiscuous inhibitor by causing protein aggregation [26] because
the presence of detergent Tween 20 had minimal effect on its
inhibition potency for bacterial topoisomerase I. The hydroxyl and
carboxyl moieties in the structure of anziaic acid point to the
possibility of divalent ion chelation as a potential mechanism of
inhibition, since divalent ions are required for the religation step of
the bacterial topoisomerase I catalytic cycle. However, the potency
of bacterial topoisomerase I inhibition did not decrease when the
concentration of Mg
2+ in the reaction shifted from 0.5 mM to
6 mM. Therefore anziaic acid did not inhibit bacterial topoisom-
erase I by competing for binding of free divalent ions. It could
potentially inhibit bacterial topoisomerase I by interacting with the
divalent ions bound at the enzyme active site, similar to the
mechanism of action of the raltegravir, an inhibitor for the strand
transfer step of HIV integrase [27]. Anziaic acid was also found to
inhibit the supercoiling activity of E. coli DNA gyrase, a type IIA
topoisomerase, although it was not found to increase the gyrase
DNA cleavage product as a poison inhibitor. Further studies are
needed to confirm that topoisomerase I is the antibacterial target
for anziaic acid.
Anziaic acid was also found to act as a poison inhibitor against
human topoisomerase IIa. This could account at least in part for
Table 2. Summary of inhibitory action of anziaic acid on topoisomerases tested.
Topoisomerase Target IC50 for Inhibition of catalytic activity Poison Inhibitor Mechanism
E. coli and Y. pestis Topo I (Type IA) 14–19 mMY e s
E. coli DNA gyrase Type IIA) 19 mMN o
Human Topo I (Type IB) 230 mMN o
Human Topo Iia (Type IIA) 35 mMY e s
doi:10.1371/journal.pone.0060770.t002
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lial cells. Human topoisomerase IIa is another member of the type
IIA topoisomerase subfamily. Type IA and type IIA topoisomerase
subfamilies share a number of structural and mechanistic
similarities including interaction with divalent ions with conserved
aspartates in the TOPRIM domain in the active site [28,29]. Mg
2+
ions are required for DNA rejoining by type IA topoisomerases,
but are dispensable for DNA cleavage by this class of topoisom-
erase. In contrast, divalent ions are required for DNA cleavage by
type IIA topoisomerases. The observed effects of anzaizic acid on
the various topoisomerase activities (summarized in Table 2) are
consistent with the compound potentially interfering with Mg
2+
ions interaction in the TOPRIM domain as mechanism of action.
Such interference would still allow DNA cleavage by type IA
topoisomerases but DNA rejoining would be inhibited to result in
accumulation of type IA topoisomerase cleavage intermediate.
Type IB topoisomerases do not require divalent ions for catalysis,
and would therefore be most resistant to inhibition by anziaic acid.
It is intriguing that anziaic acid was found to act as a poison
inhibitor for human topoisomerase IIa, but inhibits the catalytic
activity of DNA gyrase without an increase in DNA cleavage
intermediate. The two metals found at the active site of these type
IIA enzymes might be affected differentially by anziaic acid,
allowing DNA cleavage to take place for human topoisomerase
IIa, but not for DNA gyrase.
Lichens not only might be eaten by animals, but also threatened
by antagonistic bacteria, and it is believed that they produce
secondary metabolites as defenses against these predators and
pathogens [30]. Depsides are common lichen natural products.
The antibacterial activity and cytotoxicity of anziaic acid from
Hypotrachyna sp. provide further evidence that depsides could be
lichens’ weapons against animals and microorganisms. Among the
,200 depsides previously identified from lichens [31], many have
antimicrobial activity, including those isolated from Origanum
dictamnus [32]. Investigation of other natural product depsides or
structural analogs of anziaic acid could lead to compounds with
greater selectivity towards bacterial topoisomerase I useful for
development of new antibacterial agents while similar compounds
with greater selectivity for human topoisomerase IIa might have
potential as novel anticancer agents. Selectivity for bacterial
topoisomerase I and decrease in cytotoxicity could potentially be
improved by substituting the lipophilic pentyl group with moieties
that can improve the binding affinities to the topoisomerase I
protein. This will be followed up in future SAR studies of anziaic
acid synthetic analogs.
Conclusions
A natural product depside was found to be a novel topoisom-
erase poison inhibitor for bacterial topoisomerase I and human
topoisomerase IIa, suggesting the exploratory potential of this class
of natural products or analogs as new antibacterial or anticancer
agents.
Supporting Information
Figure S1 NMR spectra of anziaic acid. (a)
1H NMR
spectrum. (b)
13C NMR spectrum. (c) COSY spectrum.
(d) HSQC spectrum. (e) HMBC spectrum.
(PDF)
Figure S2 NMR data of anziaic acid.
(PDF)
Figure S3 MS spectrum of anziaic acid.
(PDF)
Table S1
13C and
1H spectral data for anziaic acid in CD3OD.
(PDF)
Acknowledgments
We thank Dr. Su Chang for kind advice and support, Dr. Tao Ren and
Sean Johnston for help in assay set up, Jennifer Nale and David Wrobel for
assistance in data processing and analysis, and NERCE/NSRB for
screening libraries and the HTS facilities. We also thank Dr. Susan Olson
for kind gift of HPEAC and Jose ´ L. Chaves for the identification of the
Lichen sample.
Author Contributions
Conceived and designed the experiments: BC TA YT SC JC. Performed
the experiments: BC TA VV. Analyzed the data: BC TA YT SC JC VV
GT. Contributed reagents/materials/analysis tools: BC YT SC JC VV
GT. Wrote the paper: BC YT SC.
References
1. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective.
Nat. Rev. Mol. Cell Biol. 3: 430–440.
2. Vos SM, Tretter EM, Schmidt BH, Berger JM (2011) All tangled up: how cells
direct, manage and exploit topoisomerase function. Nat. Rev. Mol. Cell Biol. 12:
827–841.
3. Pommier Y, Leo E, Zhang H, Marchand C (2010) DNA topoisomerases and
their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17: 421–433.
4. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat.
Rev. Cancer. 6: 789–802.
5. Anderson VE, Osheroff N (2001) Type II topoisomerases as targets for
quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr. Pharm. Des. 7:
337–353.
6. Arias C (2012) The rise of the Enterococcus: beyond vancomycin resistance.
Nature reviews.Microbiology 10: 266–278.
7. Carlet J (2012) Ready for a world without antibiotics? The Pensie `res Antibiotic
Resistance Call to Action. Antimicrobial resistance & infection control 1: 11.
8. Tse-Dinh YC (2009) Bacterial topoisomerase I as a target for discovery of
antibacterial compounds. Nucleic Acids Res. 37: 731–737.
9. Cheng B, Shukla S, Vasunilashorn S, Mukhopadhyay S, Tse-Dinh YC (2005)
Bacterial cell killing mediated by topoisomerase I DNA cleavage activity. J. Biol.
Chem. 280: 38489–38495.
10. Cheng B, Annamalai T, Sorokin E, Abrenica M, Aedo S, et al.(2009) Asp-to-Asn
substitution at the first position of the DxD TOPRIM motif of recombinant
bacterial topoisomerase I is extremely lethal to E. coli. J. Mol. Biol. 385: 558–567.
11. Narula G, Annamalai T, Aedo S, Cheng B, Sorokin E, et al. (2011) The strictly
conserved Arg-321 residue in the active site of Escherichia coli topoisomerase I
plays a critical role in DNA rejoining. J. Biol. Chem. 286: 18673–18680.
12. Liu IF, Annamalai T, Sutherland JH, Tse-Dinh YC (2009) Hydroxyl radicals are
involved in cell killing by the bacterial topoisomerase I cleavage complex. J.
Bacteriol. 191: 5315–5319.
13. Dwyer DJ, Kohanski MA, Collins JJ (2009) Role of reactive oxygen species in
antibiotic action and resistance. Curr.Opin.Microbiol. 12: 482–489.
14. Dwyer DJ, Kohanski MA, Hayete B, Collins JJ (2007) Gyrase inhibitors induce
an oxidative damage cellular death pathway in Escherichia coli. Mol. Syst. Biol.
3: 91.
15. Abreu A (2012) Plants as sources of new antimicrobials and resistance-modifying
agents. Nat. Prod. Rep. 29: 1007.
16. Sorokin EP, Cheng B, Rathi S, Aedo SJ, Abrenica MV, et al. (2008) Inhibition
of Mg
2+ binding and DNA religation by bacterial topoisomerase I via
introduction of an additional positive charge into the active site region. Nucleic
Acids Res.
17. Cao S (2010) Asterogynins: Secondary Metabolites from a Costa Rican
Endophytic Fungus. Org. Lett. 12: 4661–4663.
18. Elix JA (1974) Synthesis of para-Olivetol Depsides, Aust. J. Chem. 27: 1767–
1779.
19. Bansal S, Sinha D, Singh M, Cheng B, Tse-Dinh YC et al. (2012) 3,4-
dimethoxyphenyl bis-benzimidazole, a novel DnA topoisomerase inhibitor that
targets Escherichia coli topoisomerase I. J. Antimicrob. Chemother. 67: 2882–
2891.
20. Annamalai T, Dani N, Cheng B, Tse-Dinh YC (2009) Analysis of DNA
relaxation and cleavage activities of recombinant Mycobacterium tuberculosis DNA
topoisomerase I from a new expression and purification protocol. BMC
Biochem. 10: 18.
Depside Anziaic Acid: A New Topoisomerase Inhibitor
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e6077021. Sampson BA, Misra R, Benson SA (1989) Identification and characterization of
a new gene of Escherichia coli K-12 involved in outer membrane permeability.
Genetics 122: 491–501.
22. Braun M,Silhavy TJ (2002) Imp/OstA is required for cell envelope biogenesis in
Escherichia coli. Mol. Microbiol. 45: 1289–1302.
23. Tse-Dinh YC (1986) Uncoupling of the DNA breaking and rejoining steps of
Escherichia coli type I DNA topoisomerase. Demonstration of an active covalent
protein-DNA complex. J. Biol. Chem. 261: 10931–10935.
24. Bhat AG, Leelaram MN, Hegde SM, Nagaraja V (2009) Deciphering the
distinct role for the metal coordination motif in the catalytic activity of
Mycobacterium smegmatis topoisomerase I. J. Mol. Biol. 393: 788–802.
25. Cheng B, Sorokin EP, Tse-Dinh YC (2008) Mutation adjacent to the active site
tyrosine can enhance DNA cleavage and cell killing by the TOPRIM Gly to Ser
mutant of bacterial topoisomerase I. Nucleic Acids Res. 36: 1017–1025.
26. Coan KE, Maltby DA, Burlingame AL, Shoichet BK (2009) Promiscuous
aggregate-based inhibitors promote enzyme unfolding. J. Med. Chem. 52: 2067–
2075.
27. Evering TH, Markowitz M (2007) Raltegravir (MK-0518): an integrase inhibitor
for the treatment of HIV-1. Drugs Today (Barc) 43: 865–877.
28. Berger JM, Fass D, Wang JC, Harrison SC (1998) Structural similarities between
topoisomerases that cleave one or both DNA strands. Proc. Natl. Acad. Sci. U.
S. A. 95: 7876–7881.
29. Schmidt BH, Burgin AB, Deweese JE, Osheroff N, Berger JM (2010) A novel
and unified two-metal mechanism for DNA cleavage by type II and IA
topoisomerases. Nature 465: 641–644.
30. Rundel PW (1978) The ecological role of secondary lichen substrances.
Biochem. Syst. Ecol. 6: 157–170.
31. Podterob AP (2008) Chemical composition of lichens and their medical
applications, Pharma. Chem. J. 42: 582–588.
32. Chatzopoulou A (2010) Depsides and Other Polar Constituents from
Origanumdictamnus L. and their in Vitro Antimicrobial Activity in Clinical
Strains. J. Agric. Food Chem. 58: 6064–6068.
Depside Anziaic Acid: A New Topoisomerase Inhibitor
PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e60770